You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

DICLOFENAC SODIUM - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for diclofenac sodium and what is the scope of patent protection?

Diclofenac sodium is the generic ingredient in nine branded drugs marketed by Actavis Mid Atlantic, Alembic, Amneal, Amneal Pharms, Aurolife Pharma Llc, Cipla, Encube, Glenmark Pharms Ltd, Hikma, Padagis Israel, Perrigo Pharma Intl, Taro, Fougera Pharms, Haleon Us Holdings, Altaire Pharms Inc, Bausch And Lomb, Falcon Pharms, Rising, Rubicon, Sandoz, Sciegen Pharms Inc, Novartis, Javelin Pharms Inc, Apotex, Epic Pharma Llc, Lupin Ltd, Lupin Pharms, Novel Labs Inc, Pai Holdings Pharm, Twi Pharms, Watson Labs Inc, Zydus Lifesciences, Horizon, Nuvo Pharms Inc, Actavis Elizabeth, Aurobindo Pharma Usa, Carlsbad, Chartwell Rx, Micro Labs, Pliva, Roxane, Teva, Teva Pharms, Unique, Dexcel Ltd, Riconpharma Llc, Vpna, Pfizer, Actavis Labs Fl Inc, Exela Holdings, Yung Shin Pharm, and Zydus Pharms, and is included in seventy-two NDAs. There are twenty patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Diclofenac sodium has forty-two patent family members in fifteen countries.

There are twenty-one drug master file entries for diclofenac sodium. One hundred and twenty-nine suppliers are listed for this compound. There are three tentative approvals for this compound.

Drug Prices for DICLOFENAC SODIUM

See drug prices for DICLOFENAC SODIUM

Drug Sales Revenue Trends for DICLOFENAC SODIUM

See drug sales revenues for DICLOFENAC SODIUM

Recent Clinical Trials for DICLOFENAC SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jamia Millia IslamiaN/A
University of RijekaN/A
Fayoum University HospitalN/A

See all DICLOFENAC SODIUM clinical trials

Generic filers with tentative approvals for DICLOFENAC SODIUM
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up1.5% W/WSOLUTION;TOPICAL
⤷  Sign Up⤷  Sign Up2%SOLUTION;TOPICAL
⤷  Sign Up⤷  Sign Up2%SOLUTION;TOPICAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DICLOFENAC SODIUM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
DYLOJECT Injection diclofenac sodium 37.5 mg/mL, 1 mL single-dose vials 022396 1 2015-12-15
PENNSAID Topical Solution diclofenac sodium 2.0% 204623 1 2014-06-03
PENNSAID Topical Solution diclofenac sodium 1.5% 020947 1 2012-07-11
SOLARAZE Topical Gel diclofenac sodium 3% 021005 1 2009-12-16

US Patents and Regulatory Information for DICLOFENAC SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rubicon DICLOFENAC SODIUM diclofenac sodium TABLET, DELAYED RELEASE;ORAL 216548-001 May 11, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva DICLOFENAC SODIUM diclofenac sodium TABLET, DELAYED RELEASE;ORAL 074390-001 Aug 15, 1996 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Micro Labs DICLOFENAC SODIUM diclofenac sodium TABLET, DELAYED RELEASE;ORAL 074986-001 Feb 26, 1999 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer ARTHROTEC diclofenac sodium; misoprostol TABLET, DELAYED RELEASE;ORAL 020607-002 Dec 24, 1997 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Perrigo Pharma Intl DICLOFENAC SODIUM diclofenac sodium GEL;TOPICAL 211253-001 May 16, 2019 OTC No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Horizon PENNSAID diclofenac sodium SOLUTION;TOPICAL 204623-001 Jan 16, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Taro DICLOFENAC SODIUM diclofenac sodium SOLUTION;TOPICAL 208098-001 Sep 29, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DICLOFENAC SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis VOLTAREN diclofenac sodium TABLET, DELAYED RELEASE;ORAL 019201-001 Jul 28, 1988 ⤷  Sign Up ⤷  Sign Up
Javelin Pharms Inc DYLOJECT diclofenac sodium SOLUTION;INTRAVENOUS 022396-001 Dec 23, 2014 ⤷  Sign Up ⤷  Sign Up
Fougera Pharms SOLARAZE diclofenac sodium GEL;TOPICAL 021005-001 Oct 16, 2000 ⤷  Sign Up ⤷  Sign Up
Fougera Pharms SOLARAZE diclofenac sodium GEL;TOPICAL 021005-001 Oct 16, 2000 ⤷  Sign Up ⤷  Sign Up
Fougera Pharms SOLARAZE diclofenac sodium GEL;TOPICAL 021005-001 Oct 16, 2000 ⤷  Sign Up ⤷  Sign Up
Falcon Pharms DICLOFENAC SODIUM diclofenac sodium SOLUTION/DROPS;OPHTHALMIC 020809-001 May 4, 1998 ⤷  Sign Up ⤷  Sign Up
Falcon Pharms DICLOFENAC SODIUM diclofenac sodium SOLUTION/DROPS;OPHTHALMIC 020809-001 May 4, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DICLOFENAC SODIUM

Country Patent Number Title Estimated Expiration
Israel 222432 תערובות של תרופות דקלופנאק וביתא-ציקלודקסטרין במינון נמוך (Formulations of low dose diclofenac and beta-cyclodextrin) ⤷  Sign Up
Japan 5823093 ⤷  Sign Up
China 101410123 Formulations of low dose diclofenac and beta-cyclodextrin ⤷  Sign Up
Canada 2647348 FORMULATIONS DE DICLOFENAC ET DE CYCLODEXTRINE BETA A FAIBLEDOSAGE (FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN) ⤷  Sign Up
South Africa 200808115 FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN ⤷  Sign Up
Japan 6265964 ⤷  Sign Up
Japan 2009531450 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.